|

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

RECRUITINGSponsored by Mayo Clinic
Actively Recruiting
SponsorMayo Clinic
Started2021-04-22
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT06279572

Summary

This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults \> 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy
* Treatment naive adult acute myeloid leukemia patients

Exclusion Criteria:

* Acute myeloid leukemia patients receiving azacitidine and venetoclax as salvage therapy will be excluded
* Patients who are pregnant or breast-feeding

Conditions2

Acute Myeloid LeukemiaCancer

Locations3 sites

Arizona

1 site
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
Clinical Trials Referral Office855-776-0015mayocliniccancerstudies@mayo.edu

Florida

1 site
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980
Clinical Trials Referral Office855-776-0015mayocliniccancerstudies@mayo.edu

Minnesota

1 site
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Clinical Trials Referral Office855-776-0015mayocliniccancerstudies@mayo.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.